{"id":"W2164958589","doi":"10.1007/s00345-014-1244-2","title":"Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder","year":2014,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Astellas Pharma","keywords":"Mirabegron; Tolerability; Overactive bladder; Medicine; Placebo; Urology; Onset of action; Internal medicine; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007479515,0.001172049,0.002987689,0.0006543744,0.0003663136,0.00152299,0.0007081847,0.001614907,0.002792923],"category_scores_gemma":[0.005326005,0.000596468,0.004249005,0.0008563926,0.0008468057,0.001032583,0.0004078518,0.002219737,0.000313839],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008148755,"about_ca_system_score_gemma":0.001636668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006012388,"about_ca_topic_score_gemma":0.002070246,"domain_scores_codex":[0.9968923,0.002096192,0.0003367515,0.0002738536,0.0001944144,0.0002064964],"domain_scores_gemma":[0.9968783,0.001241037,0.001065062,0.0001490901,0.0002424278,0.0004242184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8877943,0.008449695,0.003145604,0.006813211,0.01034026,0.0001162648,0.0002181878,0.0008448329,0.01100858,0.0001875018,0.001267553,0.06981395],"study_design_scores_gemma":[0.7834871,0.1989942,0.008921539,0.0003730382,0.004605118,0.0001089188,0.00005469145,0.0003838949,0.001214809,0.0001442631,0.00168362,0.00002879177],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8517659,0.1297545,0.002710467,0.001822963,0.0006810783,0.008812464,0.001468668,0.000240768,0.002743165],"genre_scores_gemma":[0.9643597,0.02162091,0.003721559,0.001684474,0.0004029347,0.005881944,0.00114959,0.00003193456,0.001146954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007479515,"threshold_uncertainty_score":0.03955597,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06621683943050793,"score_gpt":0.4164029860685041,"score_spread":0.3501861466379962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}